title: [Prognostic significance of morbidly hematopoietic characteristics in 69 patients with myelodysplastic syndrome].
abstract: OBJECTIVE
  This study was to investigate the influence of morbidly hematopoietic characteristics on the prognosis of patients with myelodysplastic syndrome (MDS).
  
  
  METHODS
  A total of 69 cases of MDS were analyzed retrospectively on ralatienship between sex, age, MDS types, WBC count, hemoglobin (Hb) level, platelet (Plt) count at diagnosis, morbidly cytologic features of bone marrow and survival time of MDS patients.
  
  
  RESULTS
  The median survival time of 69 cases of MDS was 29.90 months. The patients of different sexes and Plt level at diagnosis did not display statistically significant difference in median survival time (P > 0.05); the patients with different ages, WBC count and Hb level showed statistically significant difference in median survival time (P < 0.05); the median survival time of patients with different MDS types was significant different (P < 0.01); the MDS patients with myeloid lineage containing nuclear plasma development imbalance, micronuclei, abnormal mitotic figures, with erythroid lineage containing megaloblastic degeneration, cell size disparity, nuclcar budding and muclear fragmentation, and with megakaryocyte lineage containing micromegaryocytes, excessive muclear leaves, displayed significant difference in median survival time (P < 0.05). The MDS patients with ALIP positive, fibrosis in bone marrow blopsy showed significant difference in median survival time.
  
  
  CONCLUSIONS
  The age, MDS types, Hb level and WBC count at diagnosis are indicators influencing the prognosis. The unbalanced development of muclear plasma, micronuclei, abnormal mitotic figures in myeloid morbid hematopoiesis, the megaloblastic degeneration, cell size disperity, muclear budding, nuclear fragmentation in erythroid morbid hematopoiesis, the micro-megakaryocytes, excessive nuclear leaves in megakaryocytic morbid hematopoiesis, and existance of ALIP posstive and fibrosis in bone marrow biopsy indicate important values for evaluation of MDS prognosis.
authors: Department of Oncology, The Third People's Hospital of Chongqing, Chongqing 400000, China.
authors: Yu-Ni
authors: YN
authors: Wu
authors: Department of Oncology, The Third People's Hospital of Chongqing, Chongqing 400000, China.
authors: Zhi-Bin
authors: ZB
authors: Luo
authors: Department of Oncology, The Third People's Hospital of Chongqing, Chongqing 400000, China.
authors: Chen
authors: C
authors: Wang
authors: Department of Oncology, The Third People's Hospital of Chongqing, Chongqing 400000, China.
authors: Jing
authors: J
authors: Li
authors: Department of Oncology, The Third People's Hospital of Chongqing, Chongqing 400000, China.
authors: Hui-Yan
authors: HY
authors: Luo
authors: Department of Oncology, The Third People's Hospital of Chongqing, Chongqing 400000, China. E-mail: 1983711@163.com.
authors: Dai-Ying
authors: DY
authors: He
mesh_terms: D000749:Anemia, Megaloblastic; D001706:Biopsy; D001853:Bone Marrow; D006801:Humans; D007958:Leukocyte Count; D008533:Megakaryocytes; D009190:Myelodysplastic Syndromes; D011379:Prognosis; D012189:Retrospective Studies